Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity

Journal of the American Society of Echocardiography

Volumn 26, Issue 5, 2013, Pages 493-498

  Negishi, Kazuaki ^a   Negishi, Tomoko ^a   Hare, James L ^b   Haluska, Brian A ^b   Plana, Juan Carlos ^a   Marwick, Thomas H ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Breast cancer; Cardiotoxicity; Strain; Strain rate; Trastuzumab

Indexed keywords

DOXORUBICIN; EPIRUBICIN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIAC PATIENT; CARDIOTOXICITY; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; GLOBAL LONGITUDINAL EARLY DIASTOLIC STRAIN RATE; GLOBAL LONGITUDINAL PEAK SYSTOLIC STRAIN; GLOBAL LONGITUDINAL PEAK SYSTOLIC STRAIN RATE; HEART INDEX; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MITRAL ANNULAR DIASTOLIC VELOCITY; MITRAL ANNULAR SYSTOLIC VELOCITY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTOLE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ECHOCARDIOGRAPHY; FEMALE; HEART; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 84876703502     PISSN: 08947317     EISSN: 10976795     Source Type: Journal    
DOI: 10.1016/j.echo.2013.02.008     Document Type: Article

References (31)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics 2010 CA Cancer J Clin 60 2010 277 300
3. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
4. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, and I. Smith Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
5. E.H. Romond, E.A. Perez, J. Bryant, V.J. Suman, C.E. Geyer Jr., and N.E. Davidson Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
6. J.R. Mackey, M. Clemons, M.A. Cote, D. Delgado, S. Dent, and A. Paterson Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group Curr Oncol 15 2008 24 35
7. A. Seidman, C. Hudis, M.K. Pierri, S. Shak, V. Paton, and M. Ashby Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 2002 1215 1221
8. J.E. Otterstad, G. Froeland, M. St. John Sutton, and I. Holme Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function Eur Heart J 18 1997 507 513
9. M.S. Ewer, and D.J. Lenihan Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 26 2008 1201 1203
10. B.W. Eidem Identification of anthracycline cardiotoxicity: left ventricular ejection fraction is not enough J Am Soc Echocardiogr 21 2008 1290 1292
11. J.L. Hare, J.K. Brown, R. Leano, C. Jenkins, N. Woodward, and T.H. Marwick Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab Am Heart J 158 2009 294 301
12. E. Ho, A. Brown, P. Barrett, R.B. Morgan, G. King, and M.J. Kennedy Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study Heart 96 2010 701 707
13. N. Fallah-Rad, J.R. Walker, A. Wassef, M. Lytwyn, S. Bohonis, and T. Fang The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy J Am Coll Cardiol 57 2011 2263 2270
14. R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, and P.A. Pellikka Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
15. M. Leitman, P. Lysyansky, S. Sidenko, V. Shir, E. Peleg, and M. Binenbaum Two-dimensional strain-a novel software for real-time quantitative echocardiographic assessment of myocardial function J Am Soc Echocardiogr 17 2004 1021 1029
16. M. Bansal, G.Y. Cho, J. Chan, R. Leano, B.A. Haluska, and T.H. Marwick Feasibility and accuracy of different techniques of two-dimensional speckle based strain and validation with harmonic phase magnetic resonance imaging J Am Soc Echocardiogr 21 2008 1318 1325
17. C. Serrano, J. Cortes, L. De Mattos-Arruda, M. Bellet, P. Gomez, and C. Saura Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors Ann Oncol 23 2012 897 902
18. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172
19. M.J. Pencina, R.B. D'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
20. G.M. Felker, R.E. Thompson, J.M. Hare, R.H. Hruban, D.E. Clemetson, and D.L. Howard Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy N Engl J Med 342 2000 1077 1084
21. M.H. Chen, S.D. Colan, and L. Diller Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers Circ Res 108 2011 619 628
22. T. Eschenhagen, T. Force, M.S. Ewer, G.W. de Keulenaer, T.M. Suter, and S.D. Anker Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 13 2011 1 10
23. H. Sawaya, I.A. Sebag, J.C. Plana, J.L. Januzzi, B. Ky, and V. Cohen Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Am J Cardiol 107 2011 1375 1380
24. V. Mor-Avi, R.M. Lang, L.P. Badano, M. Belohlavek, N.M. Cardim, and G. Derumeaux Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography J Am Soc Echocardiogr 24 2011 277 313
25. G. Tjeerdsma, M.T. Meinardi, W.T. van Der Graaf, M.P. van Den Berg, N.H. Mulder, and H.J. Crijns Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables Heart 81 1999 419 423
26. S. Tassan-Mangina, D. Codorean, M. Metivier, B. Costa, C. Himberlin, and C. Jouannaud Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study Eur J Echocardiogr 7 2006 141 146
27. G. Mercuro, C. Cadeddu, A. Piras, M. Dessi, C. Madeddu, and M. Deidda Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers Oncologist 12 2007 1124 1133
28. D. Cardinale, A. Colombo, R. Torrisi, M.T. Sandri, M. Civelli, and M. Salvatici Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 2010 3910 3916
29. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
30. D.L. Keefe Trastuzumab-associated cardiotoxicity Cancer 95 2002 1592 1600
31. H. Sawaya, I.A. Sebag, J.C. Plana, J.L. Januzzi, B. Ky, and T.C. Tan Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab Circ Cardiovasc Imaging 5 2012 596 603